Dr. Hugh Akston
Hedge fund manager, long/short equity, value

Invacare Dramatically Undervalued Due To Temporary FDA Issue

Invacare Corp. (NYSE:IVC) declined substantially following its Q2 2014 earnings report despite the fact that revenue actually came in higher than analyst expectations. We believe Mr. Market is being incredibly short-sighted on IVC and we believe the stock offers a tremendous risk/reward opportunity for those investors with longer time horizons. The company is the global leader in mobility and seating products, but it has been dramatically under-earning for the past two years due to an FDA consent decree that has temporarily shut down production of its high-margin custom power wheelchair business. IVC has maintained the production infrastructure during this period, which has dramatically impaired the profitability of the consolidated business. Furthermore, IVC has been overspending on consultants and...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details